The present, future and prospective of cfDNA
The current status of cfDNA is impressive in that detection of cancer by the use of cfDNA is gaining much enthusiasm since alterations that are tumor-specific in the cfDNA are specific to tumors and not available in the healthy cells that are not cancerous. Due to this fact, cfDNA offers provides a potentially specific and sensitive method of detecting cancer. In a similar way to CTCs, among the most significant technical limitations of cfDNA is the mapping of very low amounts of tumor cfDNA in instances where it gives an account of less than one percent of the entire circulating free DNA in the blood.
This implies that some unique standards for sequencing such as pyrosequencing or Sanger sequencing can be useful in detecting DNA in patients who are having huge tumor burden only. As a development, the development of digital polymerase chain reaction, emulsification, beads, amplification, and magnetics, or even pyrophosphorolysis-activated polymerization have made it possible to detect the cfDNA that is derived from a tumor in a manner that is considered consistent.
For prospects, more information is being accumulated, suggesting that the cfDNA will be a widely applicable, sensitive, and specific biomarker that will be used for diverse research and clinical purposes in those patients having multiple various types of cancer. In the same methodology, that the tumor molecular profiling is applied in the detection of actionable mutations for therapy choice, liquid biopsies may provide a superior method that is an alternative for detecting mutations to direct selection of therapy in patients that are not able to go through tissue biopsy.
Shortly with continued development, apart from cfDNA being used for disease prognosis, technology can be enhanced for cfDNA to be used for predicting clinical outcomes.